ACIP

Next ACIP Meeting

October 19, 2022: 8:30am – 5:30pm ET

October 20, 2022: 8:30am – 4:00pm ET

These meetings are virtual. No registration is required to watch the webcasts.

Federal Register

Contact ACIP Secretariat

1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
acip@cdc.gov

email_03Get Email Updates

To receive email updates about this page, enter your email address:

Meeting Recommendations
June 2022

ACIP approved the following recommendations by majority vote at its June 22-23, 2022 meeting:

  • ACIP recommends that adults aged ≥65 years preferentially receive one of the following influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4).  If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.
  • Affirm the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022-23 Influenza Season.”
  • PCV15 (15-valent pneumococcal conjugate vaccine) may be used as an option to PCV13 (13-valent pneumococcal conjugate vaccine) for children aged <19 years according to currently recommended PCV13 dosing and schedules.
  • MMR vaccine (Priorix, GSK) according to currently recommended schedules and off-label uses as an option to prevent measles, mumps, and rubella.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.